



© 2017 Equirus All rights reserved

Rating Information			
Price (Rs)	1,316		
Target Price (Rs)	1,394		
Target Date	30th Sep'18		
Target Set On	5 <sup>th</sup> Nov'17		
Implied yrs of growth (DCF)	20		
Fair Value (DCF)	1,268		
Fair Value (DDM)	463		
Ind Benchmark	BSETHC		
Model Portfolio Position	NA		
Stock Information			
Market Cap (RsMn)	2,23,036		
Free Float (%)	28.8%		
52 Wk H/L (Rs)	1769.5/1141.95		
Avg Daily Volume (1yr)	2,76,176		
Avg Daily Value (RsMn)	379.9		
Equity Cap (RsMn)	846		
Face Value (Rs)	5		
Bloomberg Code	TRP IN		
Ownership			
Promoters	71.3 %	0.0 %	0.0 %
DII	9.0 %	0.2 %	122.7 %
FII	9.6 %	0.4 %	-61.7 %
Public	10.2 %	-0.6 %	-61.0 %
Price %			
Absolute	5.6 %	4.9 %	-0.1 %
Vs Industry	-1.6 %	1.2 %	8.0 %
IPCALAB	6.9 %	12.7 %	-9.6 %
CADILAHC	4.8 %	-9.1 %	25.2 %
Consolidated Quarterly EPS forecast			
Rs/Share	1Q	2Q	3Q
EPS (17A)	17.3	12.2	13.5
EPS (18E)	11.1	12.0	15.2
			12.2
			14.8

# Torrent Pharmaceuticals Ltd.

2QFY18 Results: Estimate (↑), TP (↑), Rating (↑)

Regular Coverage

Absolute : ADD

Relative : Benchmark

6% ATR in 14months

Pharmaceuticals

Expanding domestic footprint with Unichem acquisition - Upgrade to ADD

Torrent Pharmaceutical Limited's (TRP) 2QFY18 results were slightly below EE owing to a topline miss due to one-offs in Brazil. However, a strong rebound in the domestic market came as a positive surprise. TRP is looking to further strengthen its domestic business by acquiring Unichem's portfolio for Rs 36bn. We think the acquisition is a good strategic fit in the backdrop of a challenging environment in the US, and believe the pay-back period would more than 8 years. On a pro-forma basis we believe acquisition will be earnings dilutive in the 1<sup>st</sup> year. We upgrade TRP to ADD with a Sep'18 TP of Rs 1,394 derived by assigning 25x P/E (vs. 22x earlier) - higher owing to TRP's increasing focus on the domestic business.

**US biz declines marginally qoq:** The US business declined by Rs 170mn sequentially with revenues at Rs 2.55bn. TRP has approvals in place for five ANDAs, viz. *gLuvox Cr* (two generic players), *gTribenzor* (two generic players), *gTwynsta*, *gLamictan Xr* and *gAgrylin*, and expects to launch all of them over the next two quarters. Since most of these are small products, we expect US\$ 3mn per ANDA from these launches. From a long-term perspective, the company remains optimistic on the US market, and stated its goal of clocking US\$ 250mn in revenues, which would mainly be led by new launches. TRP has guided for four derma ANDA filings by fiscal-end, and reiterated its guidance of 10-15 ANDA filings per annum.

**Domestic biz rebounds sharply with 22% growth:** Domestic business grew 22% on a yoy basis and 27% yoy on a like-to-like basis (at gross level) mainly on account of post- GST restocking. TRP remains confident on its domestic biz; to strengthen its footprint, it has entered into a definite agreement with Unichem for acquiring its domestic portfolio for Rs 36bn. The acquisition would be consummated by Dec'17.

**Unichem acquisition a strategic fit:** TRP is strong in cardiology/gastro/CNS therapies with market shares of 5.6%/3.1%/ 6.4%. With the Unichem portfolio acquisition, TRP's share in these therapies is set to increase to 3.2%/ 8.6%/3.9%/8.4%. The acquisition would also improve TRP's ranking in the cardio (from 16 to 8) and gastro (from 3 to 2) segments. Along with Unichem's portfolio, TRP would be taking over its field force (3,000) and new stockists (2,000).

**Synergies; low-hanging fruits to be plucked first:** TRP stated that it sees synergies in revenues and costs from the acquisition over the coming period. We believe some of these synergies would be in the form of increase in drug prices, field force rationalization and improvement in sales-force productivity (Unichem's Rs. 0.27mn vs. TRP's Rs 0.72mn - sales force productivity). With this, TRP expects the acquisition to be cash-accractive from the first year and EPS accretive by third year.

## Change in estimates

Rs. Mn	FY18E	Chg (%)	FY19E	Chg (%)
Sales	60,336	-1%	69,850	0%
EBITDA	13,708	4%	15,719	3%
EPS (Rs.)	53	3%	61	4%

## Consolidated Financials

Rs. Mn YE Mar	FY17A	FY18E	FY19E	FY20E
Sales	58,510	60,336	69,850	79,351
EBITDA	13,770	13,708	15,719	18,207
Depreciation	3,070	3,420	3,780	4,055
Interest Expense	2,060	2,191	2,241	2,241
Other Income	2,230	3,530	3,492	3,174
Reported PAT	9,330	9,024	10,420	11,917
Recurring PAT	9,330	9,024	10,420	11,917
Total Equity	43,510	49,895	57,268	65,699
Gross Debt	22,410	22,410	22,410	22,410
Cash	16,980	11,602	17,223	22,680
Rs Per Share	FY17A	FY18E	FY19E	FY20E
Earnings	54.9	53.1	61.3	70.1
Book Value	256	294	337	386
Dividends	13.9	13.3	15.3	17.5
FCFF	23.7	9.8	61.4	63.0
P/E (x)	24.0	24.8	21.5	18.8
P/B (x)	5.1	4.5	3.9	3.4
EV/EBITDA (x)	16.8	17.1	14.6	12.3
ROE (%)	24 %	19 %	19 %	19 %
Core ROIC (%)	19 %	14 %	15 %	22 %
EBITDA Margin (%)	24 %	23 %	23 %	23 %
Net Margin (%)	16 %	15 %	15 %	15 %

### Unichem acquisition - Other highlights

**Deal valuations reasonable:** Unichem's domestic portfolio has been valued at 4.2x sales and ~20x EV/EBITDA - which we think is reasonable considering its existing margins of 20-21% which can be easily expanded, and some legacy brands (*Unienzyme*, *Ampoxin* and *Losar*) which offer significant growth potential, as per the company. Even in comparison to previous acquisitions in the domestic space, we think the deal is reasonably valued. We believe the payback period would be more than 8 years.

**Funding via mix of internal accruals and debt:** TRP stated it would be funding the acquisition through internal accruals and debt. The company is looking to borrow 70-75% (Rs 25bn-27bn) of the acquisition cost and fund the rest through internal accruals.

**Threats:** Biggest threat would be government enforcement of 'one company, one brand and one price' policy mentioned in the draft gazette.

### Earnings call takeaways

- In Brazil, TRP made one-time provisions related to inventory fill-ups at the retail level, in anticipation of future charge-backs. The company also gave additional discounts to distributors during the quarter.
- The acquired brands from Sandoz have started ramping up.
- TRP stated that price erosion in the US market has been as severe as 15%; the company has been able to partly offset this through new launches and volume increases.
- R&D spends would be more focused towards US, India, Brazil and Germany. TRP mentioned its focus is to target complex generics for which it has already identified molecules and hired new scientists.
- TRP indicated it won't be required to hive-off any product because of the Unichem acquisition.

### Exhibit-1: Previous Acquisition in Domestic market


Other domestic acquisitions	EV/Sales	EV/EBITDA
Torrent Pharma - Elder	5.0	14
Piramal - Abbott	8.8	29
Torrent Pharma-Unichem	4.2	20

### Exhibit-2: Unichem Top 10 brands and its contribution to Domestic revenues

Brands	MAT sales	Contribution to domestic revenues
Losar Group	2020	20%
Ampoxin Group	870	9%
Unienzyme	600	6%
Telsar Group	580	6%
Vizylac	430	4%
Olsar Group	370	4%
Pregaba Group	330	3%
Trika Group	260	3%
Serta	230	2%
Arkamin Group	220	2%
<b>Total</b>	<b>5910</b>	<b>60%</b>


\*Sales as per AIOC

**Exhibit 3: Post-acquisition Torrent will have 7th largest market share from 14 currently**




Source: Company, Equirus Securities

**Exhibit 4: Unichem: Therapy-wise contribution**




Source: Company, Equirus Securities

**Exhibit 5: TRP: Therapy-wise contribution**



Source: Company, Equirus Securities

**Exhibit 6: Post acquisition therapy-wise contribution**



Source: Company, Equirus Securities



## Quarterly performance, consolidated

	Q2FY18	Q2FY18E	Q1FY18	Q2FY17	% Change			Comments
					Q2FY18E	Q1FY18	Q2FY17	
Net Sales	14,290	14,969	13,740	14,290	-5%	4%	0%	
Cost of Goods Sold	4,180	4,841	4,010	4,010	-14%	4%	4%	
Employee Cost	2,830	2,750	2,630	2,590	3%	8%	9%	
Other Expenditure	2,920	3,150	3,120	3,290	-7%	-6%	-11%	
Research & Development Expenditure	1,070	1,100	1,010	1,110	-3%	6%	-4%	
Total Expenditures	11000	11841	10770	11000	-7%	2%	0%	
EBITDA	3290	3128	2970	3290	5%	11%	0%	
Depreciation	840	890	800	690	-6%	5%	22%	
EBIT	2,450	2,238	2,170	2,600	9%	13%	-6%	
Interest	510	560	560	510	-9%	-9%	0%	
Other Income	780	1,000	1,050	430	-22%	-26%	81%	
PBT	2,720	2,678	2,660	2,520	2%	2%	8%	
Tax	680	536	780	460	27%	-13%	48%	
PAT before MI & Associates	2040	2142	1880	2060	-5%	9%	-1%	
Recurring PAT	2,040	2,142	1,880	2,060	-5%	9%	-1%	
Reported PAT	2,040	2,142	1,880	2,060	-5%	9%	-1%	
EPS (Rs)	12.0	12.6	11.1	12.2	-5%	9%	-1%	
EBITDA Margin	23%	21%	22%	23%	213	141	0	
EBIT Margin	17%	15%	16%	18%	219	135	-105	
PBT Margin	19%	18%	19%	18%	115	-33	140	
PAT Margin	14%	14%	14%	14%	-3	59	-14	
Tax Rate	25%	20%	29%	18%	500	-432	675	



Equirus

Torrent Pharmaceuticals Ltd.

Absolute - ADD

Relative - Benchmark

6% ATR in 14 months

## Company Snapshot

### How we differ from Consensus

		Equirus	Consensus	% Diff	Comment
EPS	FY18E	53	54	-1%	We are not factoring any high value launches in FY18&19E.
	FY19E	61	67	-9%	
Sales	FY18E	60,336	62,533	-4%	
	FY19E	69,850	71,555	-2%	
PAT	FY18E	9,024	9,096	-1%	
	FY19E	10,420	11,376	-8%	

### Our Key Investment arguments:

- Dearth of any meaningful opportunities in the near term.
- Pricing pressure in the base portfolio as well as delay in key launches.
- INR appreciation to pressurize margins further.

### Exhibit-7:Revenue break-up

Segments	FY16A	FY17A	FY18E	FY19E	FY20E
Domestic (exc Elder)	18,360	19,700	22,215	25,404	29,215
Growth YoY	14.0%	7.3%	12.8%	14.4%	15.0%
% of sales	27.8%	34.0%	37.2%	37.0%	37.4%
Brazil (RsMn)	5,060	6,990	7,135	8,147	9,125
Growth YoY	-16.5%	38.1%	2.1%	14.2%	12.0%
% of sales	7.7%	12.1%	11.9%	11.9%	11.7%
US (Rs. Mn)	26,709	13,470	11,317	13,423	15,165
Growth YoY	222.3%	-49.6%	-16.0%	18.6%	13.0%
% of sales	40.5%	23.3%	18.9%	19.6%	19.4%
EU + ROW	11,830	12,814	13,969	16,064	18,473
Growth YoY	-9.6%	8.3%	9.0%	15.0%	15.0%
% of sales	17.9%	22.1%	23.4%	23.4%	23.6%
Contract + Other Incomes	4,050	4,940	5,101	5,611	6,172
Growth YoY	42.1%	22.0%	3.3%	10.0%	10.0%
% of sales	6.1%	8.5%	8.5%	8.2%	7.9%
Total	66,009	57,914	59,736	68,650	78,151
Growth (%)	42.3%	-12.3%	3.1%	14.9%	13.8%

### Risk to Our View

- Improvement in margins owing to any unexpected fall in INR/USD rate.
- Unexpected launch of any high-value products.

### Key Triggers

- INR/USD appreciation.
- Time taken in launching existing products which are approved but not launched.

Sensitivity to Key Variables	% Change	% Impact on EPS
EBITDA Margin	-1 %	-3 %
-	-	-

### DCF Valuations & Assumptions

Rf	Beta	Ke	Term. Growth	Debt/IC in Term. Yr
6.9 %	0.8	11.7 %	5.0 %	34.4 %

	FY18E	FY19E	FY20-22E	FY23-27E	FY28-37E
Sales Growth	3 %	16 %	16 %	14 %	10 %
NOPAT Margin	13 %	14 %	15 %	15 %	15 %
IC Turnover	0.95	1.07	1.50	1.50	1.50
RoIC	13.6 %	14.7 %	26.5 %	28.6 %	28.1 %
Years of strong growth	1	2	5	10	20
Valuation as on date (Rs)	347	412	743	947	1,148
Valuation as of Sep'18	384	455	821	1,046	1,268

Based on DCF, assuming 20 years of growth and ~26% average ROIC, we derive current the fair value of Rs 1,148 and a Sep'18 fair value of Rs 1,268.

### Company Description:

Torrent Pharmaceuticals Limited (TPL) is a mid-sized Indian Pharmaceutical company with Global operations. It is one of the leading players in domestic formulations business with strong market presence in CVS& CNS segments. It has presence in Brazil, Mexico, US, Europe, Russia, CIS, Thailand and other developed & emerging markets of the world. TPL has a strong chronic disease drug portfolio with prime focus on cardiovascular, neuro-psychiatry and anti-diabetes segments. Over the past 5 years, revenues have grown at healthy 20% growth rate. TPL also caters to CRAMS business with ~10% of its revenues coming from insulin manufacturing business for Novo-Nordisc.

Comparable valuation			Mkt Cap	Price	Target	EPS			P/E		BPS	P/B		RoE		Div Yield		
Company	Reco.	CMP	Rs. Mn.	Target	Date	FY17A	FY18E	FY19E	FY17A	FY18E	FY17A	FY18E	FY17A	FY18E	FY19E	FY17A	FY18E	
Torrent Pharma	ADD	1,316	2,22,689	1,394	30 <sup>th</sup> Sep'18	54.9	53.1	61.3	24.0	24.8	21.5	255.9	4.5	24 %	19 %	19 %	1.1 %	1.0 %
IPCA	Short	527	66,512	444	30th Jun'18	15.4	11.9	22.0	34.2	44.2	23.9	194.6	2.6	8 %	6 %	10 %	0.8 %	0.8 %
Cadila Healthcare	Long	496	5,08,237	530	31st Dec'18	13.7	17.9	25.2	36.2	27.8	19.7	68.0	6.0	23 %	24 %	28 %	0.6 %	0.6 %






## Consolidated Quarterly Earnings Forecast and Key Drivers

Rs in Mn	1Q17A	2Q17A	3Q17A	4Q17A	1Q18A	2Q18A	3Q18E	4Q18E	1Q19E	2Q19E	3Q19E	4Q19E	FY17A	FY18E	FY19E	FY20E
Revenue	15,450	14,290	14,430	14,340	13,740	14,290	16,133	16,173	16,575	16,527	18,451	18,297	58,510	60,336	69,850	79,351
Cost of Goods Sold	4,370	4,010	4,640	4,900	4,010	4,180	5,383	5,397	5,371	5,355	5,990	5,939	17,920	18,970	22,654	25,790
Employee Cost	2,520	2,590	2,330	2,490	2,630	2,830	2,750	2,750	2,946	3,170	3,080	3,080	9,930	10,960	12,275	13,748
Other Expenditure	3,280	3,290	3,350	2,800	3,120	2,920	3,000	3,200	3,494	3,270	3,360	3,584	12,720	12,240	13,709	15,354
Research & Development Expenditure	910	1,110	950	1,200	1,010	1,070	1,188	1,190	1,302	1,298	1,452	1,440	4,170	4,458	5,492	6,252
EBITDA	4,370	3,290	3,160	2,950	2,970	3,290	3,813	3,636	3,462	3,434	4,569	4,254	13,770	13,708	15,719	18,207
Depreciation	680	690	730	970	800	840	890	890	945	945	945	945	3,070	3,420	3,780	4,055
EBIT	3,690	2,600	2,430	1,980	2,170	2,450	2,923	2,746	2,517	2,489	3,624	3,309	10,700	10,288	11,939	14,151
Interest	490	510	480	580	560	510	560	560	560	560	560	560	2,060	2,191	2,241	2,241
Other Income	260	430	500	1,040	1,050	780	800	900	829	826	923	915	2,230	3,530	3,492	3,174
PBT	3,460	2,520	2,450	2,440	2,660	2,720	3,162	3,085	2,786	2,755	3,986	3,664	10,870	11,628	13,190	15,084
Tax	540	460	160	380	780	680	579	565	585	579	837	769	1,540	2,603	2,770	3,168
PAT bef. MI & Assoc.	2,920	2,060	2,290	2,060	1,880	2,040	2,584	2,521	2,201	2,176	3,149	2,894	9,330	9,024	10,420	11,917
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Profit from Assoc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Recurring PAT	2,920	2,060	2,290	2,060	1,880	2,040	2,584	2,521	2,201	2,176	3,149	2,894	9,330	9,024	10,420	11,917
Extraordinaries	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Reported PAT	2,920	2,060	2,290	2,060	1,880	2,040	2,584	2,521	2,201	2,176	3,149	2,894	9,330	9,024	10,420	11,917
EPS (Rs)	17.25	12.17	13.53	12.17	11.06	12.00	15.20	14.83	12.95	12.80	18.52	17.03	54.88	53.08	61.30	70.10
Key Drivers																
Domestic formulations Revenues	5,040	4,960	5,030	4,670	4,640	6,070	5,960	5,546	5,800	6,374	6,853	6,377	19,700	22,215	25,404	29,215
Brazil Revenues	1,670	1,570	1,590	2,160	1,810	1,200	1,749	2,376	2,027	1,500	1,959	2,661	6,990	7,135	8,147	9,125
US revenues	4,340	3,220	3,100	2,810	2,720	2,550	2,939	3,108	3,258	3,258	3,453	3,453	13,470	11,317	13,423	15,165
CRAMs revenues	1,110	1,100	1,430	1,180	1,320	910	1,573	1,298	1,452	1,001	1,730	1,428	4,820	5,101	5,611	6,172
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sequential Growth (%)																
Revenue	3 %	-8 %	1 %	-1 %	-4 %	4 %	13 %	0 %	2 %	0 %	12 %	-1 %	-	-	-	-
Cost of Goods Sold	6 %	-8 %	16 %	6 %	-18 %	4 %	29 %	0 %	0 %	0 %	12 %	-1 %	-	-	-	-
EBITDA	-10 %	-25 %	-4 %	-7 %	1 %	11 %	16 %	-5 %	-5 %	-1 %	33 %	-7 %	-	-	-	-
EBIT	-13 %	-30 %	-7 %	-19 %	10 %	13 %	19 %	-6 %	-8 %	-1 %	46 %	-9 %	-	-	-	-
Recurring PAT	3 %	-29 %	11 %	-10 %	-9 %	9 %	27 %	-2 %	-13 %	-1 %	45 %	-8 %	-	-	-	-
EPS	3 %	-29 %	11 %	-10 %	-9 %	9 %	27 %	-2 %	-13 %	-1 %	45 %	-8 %	-	-	-	-
Yearly Growth (%)																
Revenue	-21 %	-15 %	-6 %	-5 %	-11 %	0 %	12 %	13 %	21 %	16 %	14 %	13 %	-12 %	3 %	16 %	14 %
EBITDA	-52 %	-54 %	-48 %	-39 %	-32 %	0 %	21 %	23 %	17 %	4 %	20 %	17 %	-49 %	0 %	15 %	16 %
EBIT	-57 %	-60 %	-56 %	-53 %	-41 %	-6 %	20 %	39 %	16 %	2 %	24 %	21 %	-57 %	-4 %	16 %	19 %
Recurring PAT	-35 %	-64 %	-53 %	-27 %	-36 %	-1 %	13 %	22 %	17 %	7 %	22 %	15 %	-48 %	-3 %	15 %	14 %
EPS	-35 %	-64 %	-53 %	-27 %	-36 %	-1 %	12 %	22 %	17 %	7 %	22 %	15 %	-48 %	-3 %	15 %	14 %
Margin (%)																
EBITDA	28 %	23 %	22 %	21 %	22 %	23 %	24 %	22 %	21 %	21 %	25 %	23 %	24 %	23 %	23 %	23 %
EBIT	24 %	18 %	17 %	14 %	16 %	17 %	18 %	17 %	15 %	15 %	20 %	18 %	18 %	17 %	17 %	18 %
PBT	22 %	18 %	17 %	17 %	19 %	19 %	20 %	19 %	17 %	17 %	22 %	20 %	19 %	19 %	19 %	19 %
PAT	19 %	14 %	16 %	14 %	14 %	14 %	16 %	16 %	13 %	13 %	17 %	16 %	16 %	15 %	15 %	15 %

**Consolidated Financials**

P&L (Rs Mn)	FY17A	FY18E	FY19E	FY20E
Revenue	58,510	60,336	69,850	79,351
Op. Expenditure	44,740	46,628	54,130	61,144
EBITDA	13,770	13,708	15,719	18,207
Depreciation	3,070	3,420	3,780	4,055
EBIT	10,700	10,288	11,939	14,151
Interest Expense	2,060	2,191	2,241	2,241
Other Income	2,230	3,530	3,492	3,174
PBT	10,870	11,628	13,190	15,084
Tax	1,540	2,603	2,770	3,168
PAT bef. MI & Assoc.	9,330	9,024	10,420	11,917
Minority Interest	0	0	0	0
Profit from Assoc.	0	0	0	0
Recurring PAT	9,330	9,024	10,420	11,917
Extraordinaires	0	0	0	0
Reported PAT	9,330	9,024	10,420	11,917
FDEPS (Rs)	54.9	53.1	61.3	70.1
DPS (Rs)	13.9	13.3	15.3	17.5
CEPS (Rs)	72.9	73.2	83.5	94.0
FCFPS (Rs)	23.7	9.8	61.4	63.0
BVPS (Rs)	255.9	293.5	336.9	386.5
EBITDAM (%)	24 %	23 %	23 %	23 %
PATM (%)	16 %	15 %	15 %	15 %
Tax Rate (%)	14 %	22 %	21 %	21 %
Sales Growth (%)	-12 %	3 %	16 %	14 %
FDEPS Growth (%)	-48 %	-3 %	15 %	14 %

**TTM P/E vs. 2 yr forward EPS growth**

**TTM EV/EBITDA vs. 2 yr forward EBITDA growth**

**TTM P/B vs. 2 yr forward RoE**




## Historical Consolidated Financials

P&L (Rs Mn)	FY14A	FY15A	FY16A	FY17A
Revenue	41,847	46,535	66,800	58,510
Op. Expenditure	32,332	36,333	39,570	44,740
EBITDA	9,515	10,202	27,230	13,770
Depreciation	870	1,907	2,440	3,070
EBIT	8,645	8,294	24,790	10,700
Interest Expense	586	1,752	1,860	2,060
Other Income	381	2,856	2,690	2,230
PBT	8,440	9,398	25,620	10,870
Tax	1,801	1,888	7,780	1,540
PAT bef. MI & Assoc.	6,639	7,510	17,840	9,330
Minority Interest	0	0	0	0
Profit from Assoc.	0	0	0	0
Recurring PAT	6,639	7,510	17,840	9,330
Extraordinaires	0	0	0	0
Reported PAT	6,639	7,510	17,840	9,330
EPS (Rs)	39.2	44.4	105.4	54.9
DPS (Rs)	23.0	11.3	0.0	13.9
CEPS (Rs)	44.4	55.6	119.8	72.9
FCFPS (Rs)	17.1	-71.6	120.2	23.7
BVPS (Rs)	112.4	147.1	200.2	255.9
EBITDAM (%)	23 %	22 %	41 %	24 %
PATM (%)	16 %	16 %	27 %	16 %
Tax Rate (%)	21 %	20 %	30 %	14 %
Sales growth (%)	30 %	11 %	44 %	-12 %
FDEPS growth (%)	41 %	13 %	138 %	-48 %

Balance Sheet (Rs Mn)	FY14A	FY15A	FY16A	FY17A	Cash Flow (Rs Mn)	FY14A	FY15A	FY16A	FY17A
Equity Capital	846	846	846	850	PBT	8,440	9,398	25,620	10,870
Reserve	18,178	24,059	33,040	42,660	Depreciation	870	1,907	2,440	3,070
Networth	19,024	24,906	33,886	43,510	Others	498	1,472	4,037	863
Long Term Debt	9,549	25,042	18,670	22,410	Taxes Paid	2,617	582	582	582
Def Tax Liability	2,479	4,038	4,730	3,720	Change in WC	-1,197	-4,094	-4,094	-4,094
Minority Interest	4	4	0	0	Operating C/F	5,994	8,102	27,421	10,127
Account Payables	14,291	18,277	22,600	22,980	Capex	-3,982	-21,964	-7,702	-6,157
Other Curr Liabi	5,350	6,842	10,210	8,630	Change in Invest	106	160	491	720
Total Liabilities & Equity	50,698	79,110	90,096	1,01,250	Others	318	182	-1,168	-2,433
Net Fixed Assets	8,753	28,168	39,190	36,890	Investing C/F	-3,558	-21,623	-8,379	-7,869
Capital WIP	5,341	6,783	0	5,190	Change in Debt	4,141	16,062	-3,837	2,020
Others	1,264	1,503	2,570	5,310	Change in Equity	0	0	0	0
Inventory	10,061	10,672	13,580	15,590	Others	-3,901	-3,442	-10,831	-4,067
Account Receivables	10,994	15,945	14,450	13,440	Financing C/F	240	12,620	-14,668	-2,046
Other Current Assets	4,734	7,390	6,270	7,850	Net change in cash	2,676	-901	4,375	212
Cash	9,551	8,650	14,036	16,980	RoE (%)	40 %	34 %	61 %	24 %
Total Assets	50,698	79,111	90,096	1,01,250	RoIC (%)	27 %	21 %	34 %	17 %
Non-cash Working Capital	6,148	8,887	1,490	5,270	Core RoIC (%)	35 %	19 %	38 %	19 %
Cash Conv Cycle	53.6	69.7	8.1	32.9	Div Payout (%)	12 %	11 %	0 %	30 %
WC Turnover	6.8	5.2	44.8	11.1	P/E	33.5	29.7	12.5	24.0
FA Turnover	3.0	1.3	1.7	1.4	P/B	11.7	8.9	6.6	5.1
Net D/E	0.0	0.7	0.1	0.1	P/FCFF	76.9	-18.4	11.0	55.6
Revenue/Capital Employed	1.6	1.1	1.2	0.9	EV/EBITDA	23.9	24.2	8.7	16.8
Capital Employed/Equity	1.5	1.6	1.9	1.9	EV/Sales	5.4	5.3	3.5	4.0

Equirus Securities						
Research Analysts	Sector/Industry	Email		Equity Sales	E-mail	
Abhishek Shindadkar	IT Services	<a href="mailto:abhishek.shindadkar@equirus.com">abhishek.shindadkar@equirus.com</a>	91-22-43320643	Vishad Turakhia	<a href="mailto:vishad.turakhia@equirus.com">vishad.turakhia@equirus.com</a>	91-22-43320633
Ashutosh Tiwari	Auto, Metals & Mining	<a href="mailto:ashutosh@equirus.com">ashutosh@equirus.com</a>	91-79-61909517	Subham Sinha	<a href="mailto:subham.sinha@equirus.com">subham.sinha@equirus.com</a>	91-22-43320631
Depesh Kashyap	Mid-Caps	<a href="mailto:depesh.kashyap@equirus.com">depesh.kashyap@equirus.com</a>	91-79-61909528	Sweta Sheth	<a href="mailto:sweta.sheth@equirus.com">sweta.sheth@equirus.com</a>	91-22-43320634
Devam Modi	Power & Infrastructure	<a href="mailto:devam@equirus.com">devam@equirus.com</a>	91-79-61909516	Viral Desai	<a href="mailto:viral.desai@equirus.com">viral.desai@equirus.com</a>	91-22-43320635
Dhaval Dama	FMCG, Mid-Caps	<a href="mailto:dhaval.dama@equirus.com">dhaval.dama@equirus.com</a>	91-79-61909518	<b>Dealing Room</b>	<b>E-mail</b>	
Manoj Gori	Consumer Durables	<a href="mailto:manoj.gori@equirus.com">manoj.gori@equirus.com</a>	91-79-61909523	Ashish Shah	<a href="mailto:ashishshah@equirus.com">ashishshah@equirus.com</a>	91-22-43320662
Maulik Patel	Oil and Gas	<a href="mailto:maulik@equirus.com">maulik@equirus.com</a>	91-79-61909519	Ilesh Savla	<a href="mailto:ilesh.savla@equirus.com">ilesh.savla@equirus.com</a>	91-22-43320666
Praful Bohra	Pharmaceuticals	<a href="mailto:praful.bohra@equirus.com">praful.bohra@equirus.com</a>	91-79-61909532	Manoj Kejriwal	<a href="mailto:manoj.kejriwal@equirus.com">manoj.kejriwal@equirus.com</a>	91-22-43320663
Rohan Mandora	Banking & Financial Services	<a href="mailto:rohan.mandora@equirus.com">rohan.mandora@equirus.com</a>	91-79-61909529	Dharmesh Mehta	<a href="mailto:dharmesh.mehta@equirus.com">dharmesh.mehta@equirus.com</a>	91-22-43320661
<b>Associates</b>		<b>E-mail</b>		Sandip Amrutiya	<a href="mailto:sandipamrutiya@equirus.com">sandipamrutiya@equirus.com</a>	91-22-43320660
Ankit Choudhary		<a href="mailto:ankit.choudhary@equirus.com">ankit.choudhary@equirus.com</a>	91-79-61909533	<b>Compliance Officer</b>	<b>E-mail</b>	
Bharat Celly		<a href="mailto:bharat.celly@equirus.com">bharat.celly@equirus.com</a>	91-79-61909524	Jay Soni	<a href="mailto:jay.soni@equirus.com">jay.soni@equirus.com</a>	91-79-61909561
Harshit Patel		<a href="mailto:harshit.patel@equirus.com">harshit.patel@equirus.com</a>	91-79-61909522	<b>Corporate Communications</b>	<b>E-mail</b>	
Meet Chande		<a href="mailto:meet.chande@equirus.com">meet.chande@equirus.com</a>	91-79-61909513	Mahdokht Bharda	<a href="mailto:mahdokht.bharda@equirus.com">mahdokht.bharda@equirus.com</a>	91-22-43320647
Parva Soni		<a href="mailto:parva.soni@equirus.com">parva.soni@equirus.com</a>	91-79-61909521			
Pranav Mehta		<a href="mailto:pranav.mehta@equirus.com">pranav.mehta@equirus.com</a>	91-79-61909514			
Ronak Soni		<a href="mailto:Ronak.soni@equirus.com">Ronak.soni@equirus.com</a>	91-79-61909525			
Samkit Shah		<a href="mailto:samkit.shah@equirus.com">samkit.shah@equirus.com</a>	91-79-61909520			
Shreepal Doshi		<a href="mailto:shreepal.doshi@equirus.com">shreepal.doshi@equirus.com</a>	91-79-61909541			
Varun Baxi		<a href="mailto:varun.baxi@equirus.com">varun.baxi@equirus.com</a>	91-79-61909527			
Vikas Jain		<a href="mailto:vikas.jain@equirus.com">vikas.jain@equirus.com</a>	91-79-61909531			
<b>Rating &amp; Coverage Definitions:</b>						
<b>Absolute Rating</b>						
<ul style="list-style-type: none"> <li>LONG : Over the investment horizon, ATR &gt;= Ke for companies with Free Float market cap &gt; Rs 5 billion and ATR &gt;= 20% for rest of the companies</li> <li>ADD: ATR &gt;= 5% but less than Ke over investment horizon</li> <li>REDUCE: ATR &gt;= negative 10% but &lt;5% over investment horizon</li> <li>SHORT: ATR &lt; negative 10% over investment horizon</li> </ul>						
<b>Relative Rating</b>						
<ul style="list-style-type: none"> <li>OVERWEIGHT: Likely to outperform the benchmark by at least 5% over investment horizon</li> <li>BENCHMARK: likely to perform in line with the benchmark</li> <li>UNDERWEIGHT: likely to under-perform the benchmark by at least 5% over investment horizon</li> </ul>						
<b>Investment Horizon</b>						
Investment Horizon is set at a minimum 3 months to maximum 18 months with target date falling on last day of a calendar quarter.						
<b>Lite vs. Regular Coverage vs. Spot Coverage</b>						
We aim to keep our rating and estimates updated at least once a quarter for Regular Coverage stocks. Generally, we would have access to the company and we would maintain detailed financial model for Regular coverage companies. We intend to publish updates on Lite coverage stocks only on an opportunistic basis and subject to our ability to contact the management. Our rating and estimates for Lite coverage stocks may not be current. Spot coverage is meant for one-off coverage of a specific company and in such cases, earnings forecast and target price are optional. Spot coverage is meant to stimulate discussion rather than provide a research opinion.						
<b>Registered Office:</b>						
Equirus Securities Private Limited Unit No. 1201, 12th Floor, C Wing, Marathon Futurex, N M Joshi Marg, Lower Parel, Mumbai-400013. Tel. No: +91 - (0)22 - 4332 0600 Fax No: +91- (0)22 - 4332 0601						
<b>Corporate Office:</b>						
3rd floor, House No. 9, Magnet Corporate Park, Near Zydus Hospital, B/H Intas Sola Bridge, S.G. Highway Ahmedabad-380054 Gujarat Tel. No: +91 (0)79 - 6190 9550 Fax No: +91 (0)79 - 6190 9560						

© 2017 Equirus Securities Private Limited. All rights reserved. For Private Circulation only. This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of Equirus Securities Private Limited

**Analyst Certification**

I, Maulik Patel, author to this report, hereby certify that all of the views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

**Disclosures**

Equirus Securities Private Limited (ESPL) having Corporate Identification Number U65993MH2007PTC176044 is registered in India with Securities and Exchange Board of India (SEBI) as a trading member on the Capital Market (Reg. No. INB231301731), Futures & Options Segment (Reg. No. INF231301731) of the National Stock Exchange of India Ltd. (NSE) and on Cash Segment (Reg. No. INB011301737) of Bombay Stock Exchange Limited (BSE). ESPL is also registered with SEBI as Research Analyst under SEBI (Research Analyst) Regulations, 2014 (Reg. No. INH000001154), as a Portfolio Manager under SEBI (Portfolio Managers Regulations, 1993 (Reg. No. INP000005216) and as a Depository Participant of the Central Depository Services (India) Limited (Reg. No. IN-DP-324-2017). There are no disciplinary actions taken by any regulatory authority against ESPL. ESPL is a subsidiary of Equirus Capital Pvt. Ltd. (ECPL) which is registered with SEBI as Category I Merchant Banker and provides investment banking services including but not limited to merchant banking services, private equity, mergers & acquisitions and structured finance.

As ESPL and its associates are engaged in various financial services business, it might have: - (a) received compensation (except in connection with the preparation of this report) from the subject company for investment banking or merchant banking or brokerage services in the past twelve months; (b) managed or co-managed public offering of securities for the subject company in the past twelve months; or (c) have received a mandate from the subject company; or (d) might have other financial, business or other interests in entities including the subject company (ies) mentioned in this Report. ESPL & its associates, their directors and employees may from time to time have positions or options in the company and buy or sell the securities of the company (ies) mentioned herein. ESPL and its associates collectively do not own (in their proprietary position) 1% or more of the equity securities of the subject company mentioned in the report as the last day of the month preceding the publication of the research report. ESPL or its Analyst or Associates did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ESPL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. ESPL has not been engaged in market making activity for the subject company.

The Research Analyst engaged in preparation of this Report:-

(a) has not received any compensation from the subject company in the past twelve months; (b) has not managed or co-managed public offering of securities for the subject company in the past twelve months; (c) has not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months; (d) has not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months; (e) has not received any compensation or other benefits from the subject company or third party in connection with the research report; (f) might have served as an officer, director or employee of the subject company; (g) is not engaged in market making activity for the subject company.

This document is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ESPL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession of this document are required to inform themselves of, and to observe, such applicable restrictions. Please delete this document if you are not authorized to view the same. By reading this document you represent and warrant that you have full authority and all rights necessary to view and read this document without subjecting ESPL and affiliates to any registration or licensing requirement within such jurisdiction.

This document has been prepared solely for information purpose and does not constitute a solicitation to any person to buy, sell or subscribe any security. ESPL or its affiliates are not soliciting any action based on this report. The information and opinions contained herein is from publicly available data or based on information obtained in good faith from sources believed to be reliable but ESPL provides no guarantee as to its accuracy or completeness. The information contained herein is as on date of this report, and is subject to change or modification and any such changes could impact our interpretation of relevant information contained herein. While we would endeavour to update the information herein on reasonable basis, ESPL and its affiliates, their directors and employees are under no obligation to update or keep the information current. Also there may be regulatory, compliance, or other reasons that may prevent ESPL and its group companies from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document including the merits and risks involved. This document is intended for general circulation and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. ESPL and its group companies, employees, directors and agents accept no liability, and disclaim all responsibility, for the consequences of you or anyone else acting, or refraining to act, in reliance on the information contained in this publication or for any decision based on it. ESPL/its affiliates do and seek to do business with companies covered in its research report. Thus, investors should be aware that the firm may have conflict of interest.

A graph of daily closing prices of securities is available at <http://www.nseindia.com/ChartApp/install/charts/mainpage.jsp> and [www.bseindia.com](http://www.bseindia.com) (Choose a company from the list on the browser and select the "three years" period in the price chart).

<b>Disclosure of Interest statement for the subject Company</b>	<b>Yes/No</b>	<b>If Yes, nature of such interest</b>
Research Analyst' or Relatives' financial interest	No	
Research Analyst' or Relatives' actual/beneficial ownership of 1% or more	No	
Research Analyst' or Relatives' material conflict of interest	No	

**Disclaimer for U.S. Persons**

ESPL/its affiliates are not a registered broker-dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition Equirus is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by Equirus, including the products and services described herein are not available to or intended for U.S. persons. The information contained in this Report is not intended for any person who is a resident of the United States of America or a resident of any jurisdiction, the laws of which imposes prohibition on soliciting the securities business in that jurisdiction without going through the registration requirements and/ or prohibit the use of any information contained in this report. This Report and its respective contents do not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services and/or shall not be considered as an advertisement tool. "U.S. Persons" are generally defined as a natural person, residing in the United States or any entity organized or incorporated under the laws of the United States. US Citizens living abroad may also be deemed "US Persons" under certain rules.